A
226.10
2.15 (0.96%)
| Previous Close | 223.95 |
| Open | 224.00 |
| Volume | 324,906 |
| Avg. Volume (3M) | 675,926 |
| Market Cap | 13,814,293,504 |
| Price / Earnings (Forward) | 52.36 |
| Price / Sales | 18.74 |
| 52 Weeks Range | |
| Earnings Date | 11 Feb 2026 |
| Profit Margin | -92.67% |
| Operating Margin (TTM) | -103.23% |
| Diluted EPS (TTM) | -6.79 |
| Quarterly Revenue Growth (YOY) | 5.30% |
| Current Ratio (MRQ) | 1.04 |
| Operating Cash Flow (TTM) | -218.93 M |
| Levered Free Cash Flow (TTM) | -133.44 M |
| Return on Assets (TTM) | -22.39% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Ascendis Pharma A/S | Bullish | Bullish |
AIStockmoo Score
1.3
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 1.25 |
|
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 0.78% |
| % Held by Institutions | 113.63% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 342.00 (Barclays, 51.26%) | Buy |
| Median | 260.00 (14.99%) | |
| Low | 220.00 (Wedbush, -2.70%) | Buy |
| Average | 283.29 (25.29%) | |
| Total | 7 Buy | |
| Avg. Price @ Call | 217.18 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B of A Securities | 30 Jan 2026 | 260.00 (14.99%) | Buy | 226.10 |
| Barclays | 28 Jan 2026 | 342.00 (51.26%) | Buy | 222.45 |
| RBC Capital | 20 Jan 2026 | 250.00 (10.57%) | Buy | 215.58 |
| Wells Fargo | 20 Jan 2026 | 330.00 (45.95%) | Buy | 215.58 |
| 09 Jan 2026 | 322.00 (42.41%) | Buy | 202.99 | |
| TD Cowen | 07 Jan 2026 | 325.00 (43.74%) | Buy | 213.28 |
| Stifel | 11 Dec 2025 | 256.00 (13.22%) | Buy | 210.16 |
| Wedbush | 18 Nov 2025 | 220.00 (-2.70%) | Buy | 217.13 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |